NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
The pathological aggregation of α-synuclein (syn) is a hallmark of Parkinson's disease (PD) and related synucleinopathies. In the present study, we report a supramolecular strategy to reduce syn aggregation and its associated cellular toxicity using a panel of rationally designed anionic calix[4]-arenes. Among them, CLXP1, a tetraphosphonato derivative with a rigid, preorganized cavity, emerged as a potent inhibitor of syn aggregation in a validated yeast model of PD based on syn overexpression. CLXP1 significantly improved cell viability by reducing the formation of toxic intracellular inclusions of syn and restoring multiple dysregulated molecular pathways while preserving mitochondrial morphology and redox and lipid homeostasis and enhancing autophagic clearance. NMR analyses revealed that CLXP1 interacts with key residues of the N-terminal domain of syn, critically involved in membrane anchoring and oligomerization, supporting a model in which this interaction stabilizes the α-helical, membrane-bound conformation of syn, thereby preventing its progression toward toxic oligomeric species. These findings highlight the potential of supramolecular host-guest chemistry to selectively target intrinsically disordered proteins and provide a promising scaffold for the development of new modulators of protein aggregation.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.